Research & Innovation | National Cancer Centre Singapore

Research Cellular & Molecular Research The Division of Cellular & Molecular Research is focused on understanding the mechanistic basis of tumour development and treatment response; as well as the translation of bench-based findings to devise strategies to improve the early detection and treatment of cancers.

Research Medical Sciences The Division of Medical Sciences has evolved in the last decade to one that is completely focused on the mission of translating biological discoveries into the clinic.

Research Clinical Trials & Epidemiological Sciences The Division was conceived to provide support and to encourage clinical trials within NCCS.

Research Facilities

With almost 10,000 square metres of research space, NCCS houses advanced translational research facilities for scientists and clinician-scientists in Singapore.

Clinical Trials

At NCCS, clinical trials are led by a highly-trained multidisciplinary team of clinicians, researchers, nurses and support staff experienced in managing the protocol and delivery of local and international trials.

Our Researchers

Meet our researchers, driving innovation and uncovering groundbreaking discoveries every day.

Find a Researcher

Discover our expert researchers and their groundbreaking work in cancer, from bench to bedside, at NCCS.

Research Themes and Core Platforms

Explore our dynamic research programmes, actively pushing boundaries and sparking transformative solutions.

NCCS Research Reports

Dive into our insightful research reports, actively shaping knowledge and driving impactful discoveries.

NCCS Research Committee & Scientific Advisory Board

Research News

Patient Care Global trial shows novel treatment for triple-negative breast cancer nearly doubles survival A global, multicentre phase III trial, TROPION-Breast02, led by a senior medical oncologist and researcher from the National Cancer Centre Singapore, has demonstrated a significant breakthrough in improving the survival of patients with untreated, advanced triple negative breast cancer (TNBC) using the novel antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd).

15 Apr 2026 Read Story

Research Study uncovers the mechanisms behind tumour suppressor BAP1 protein, highlighting new treatment strategies for aggressive cancers A team of scientists led by the National Cancer Centre Singapore (NCCS) and Duke-NUS Medical School (Duke-NUS) has found a new approach for treating some of the world's most aggressive cancers associated with BAP1 mutations.

02 Apr 2026 Read Story

View All News